{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:35:18Z","timestamp":1790163318604,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00120-020-01131-x","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T13:02:43Z","timestamp":1580475763000},"page":"155-161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risikoadaptierte Therapie des\u00a0metastasierten Nierenzellkarzinoms","Risk-adapted therapy for metastatic renal cell carcinoma"],"prefix":"10.1007","volume":"59","author":[{"given":"M.-O.","family":"Grimm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Foller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"key":"1131_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2019.05.022","volume":"76","author":"L Albiges","year":"2019","unstructured":"Albiges\u00a0L, Powles\u00a0T, Staehler\u00a0M et al (2019) Updated European association of urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol 76:151\u2013156","journal-title":"Eur Urol"},{"key":"1131_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2018.11.031","volume":"108","author":"M Auvray","year":"2019","unstructured":"Auvray\u00a0M, Auclin\u00a0E, Barthelemy\u00a0P et al (2019) Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer 108:33\u201340","journal-title":"Eur J Cancer"},{"key":"1131_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(18)30778-2","volume":"20","author":"D Cella","year":"2019","unstructured":"Cella\u00a0D, Grunwald\u00a0V, Escudier\u00a0B et al (2019) Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a\u00a0randomised, phase 3 trial. Lancet Oncol 20:297\u2013310","journal-title":"Lancet Oncol"},{"key":"1131_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri\u00a0TK, Halabi\u00a0S, Sanford\u00a0BL et\u00a0al (2017) Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J\u00a0Clin Oncol 35:591\u2013597","journal-title":"J Clin Oncol"},{"key":"1131_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","volume":"94","author":"TK Choueiri","year":"2018","unstructured":"Choueiri\u00a0TK, Hessel\u00a0C, Halabi\u00a0S et al (2018) Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer 94:115\u2013125","journal-title":"Eur J Cancer"},{"key":"1131_CR6","unstructured":"Ema\/Chmp\/455620\/2019, Committee for Medicinal Products for Human Use (CHMP) Assessment report keytruda, Procedure No. EMEA\/H\/C\/003820\/II\/0069. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/keytruda-h-c-3820-ii-0069-epar-assessment-report-variation_en.pdf (Erstellt: 25. Juli 2019). Zugegriffen: 03.12.2019"},{"key":"1131_CR7","unstructured":"Ema\/Chmp\/550625\/2019, Committee for Medicinal Products for Human Use (CHMP) Assessment report Bavencio, Procedure No. EMEA\/H\/C\/004338\/II\/0009\/G. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/bavencio-h-c-004338-ii-0009-g-epar-assessment-report-variation_en.pdf (Erstellt: 19. Sept. 2019). Zugegriffen: 03.12.2019"},{"key":"1131_CR8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","volume":"30","author":"B Escudier","year":"2019","unstructured":"Escudier\u00a0B, Porta\u00a0C, Schmidinger\u00a0M et al (2019) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 30:706\u2013720","journal-title":"Ann Oncol"},{"key":"1131_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.eururo.2019.05.041","volume":"76","author":"MO Grimm","year":"2019","unstructured":"Grimm\u00a0MO, Bex\u00a0A, De Santis\u00a0M et\u00a0al (2019) Safe use of immune checkpoint inhibitors in the multidisciplinary management of urological cancer: the European association of urology position in 2019. Eur Urol 76:368\u2013380","journal-title":"Eur Urol"},{"key":"1131_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00120-018-0820-2","volume":"58","author":"MO Grimm","year":"2019","unstructured":"Grimm\u00a0MO, Tannir\u00a0NM, Motzer\u00a0RJ et al (2019) Checkmate 214 patients who discontinued first-line nivolumab + Ipilimumab or sunitinib due to treatment-related adverse events. Urologe 58:43","journal-title":"Urologe"},{"key":"1131_CR11","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng\u00a0DY, Xie\u00a0W, Regan\u00a0MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a\u00a0large, multicenter study. J\u00a0Clin Oncol 27:5794\u20135799","journal-title":"J Clin Oncol"},{"key":"1131_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/COC.0b013e31827b45f9","volume":"37","author":"J Larkin","year":"2014","unstructured":"Larkin\u00a0J, Fishman\u00a0M, Wood\u00a0L et\u00a0al (2014) Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes. Am J Clin Oncol 37:397\u2013403","journal-title":"Am J Clin Oncol"},{"key":"1131_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.20.1.289","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer\u00a0RJ, Bacik\u00a0J, Murphy\u00a0BA et al (2002) Interferon-alfa as a\u00a0comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J\u00a0Clin Oncol 20:289\u2013296","journal-title":"J Clin Oncol"},{"key":"1131_CR14","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","volume":"17","author":"RJ Motzer","year":"1999","unstructured":"Motzer\u00a0RJ, Mazumdar\u00a0M, Bacik\u00a0J et\u00a0al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J\u00a0Clin Oncol 17:2530\u20132540","journal-title":"J Clin Oncol"},{"key":"1131_CR15","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","volume":"31","author":"RJ Motzer","year":"2013","unstructured":"Motzer\u00a0RJ, Nosov\u00a0D, Eisen\u00a0T et\u00a0al (2013) Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a\u00a0phase III trial. J\u00a0Clin Oncol 31:3791\u20133799","journal-title":"J Clin Oncol"},{"key":"1131_CR16","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer\u00a0RJ, Penkov\u00a0K, Haanen\u00a0J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N\u00a0Engl J Med 380:1103\u20131115","journal-title":"N Engl J Med"},{"key":"1131_CR17","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","volume":"20","author":"RJ Motzer","year":"2019","unstructured":"Motzer\u00a0RJ, Rini\u00a0BI, Mcdermott\u00a0DF et al (2019) Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a\u00a0randomised, controlled, phase 3 trial. Lancet Oncol 20:1370\u20131385","journal-title":"Lancet Oncol"},{"key":"1131_CR18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer\u00a0RJ, Tannir\u00a0NM, Mcdermott\u00a0DF et al (2018) Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N\u00a0Engl J Med 378:1277\u20131290","journal-title":"N Engl J Med"},{"key":"1131_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41416-018-0164-0","volume":"119","author":"T Powles","year":"2018","unstructured":"Powles\u00a0T, Motzer\u00a0RJ, Escudier\u00a0B et\u00a0al (2018) Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 119:663\u2013669","journal-title":"Br J Cancer"},{"key":"1131_CR20","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini\u00a0BI, Escudier\u00a0B, Tomczak\u00a0P et\u00a0al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a\u00a0randomised phase 3 trial. Lancet 378:1931\u20131939","journal-title":"Lancet"},{"key":"1131_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","volume":"21","author":"BI Rini","year":"2020","unstructured":"Rini BI, Pal SK, Escudier BJ et al (2020) Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a\u00a0phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol 21:95\u2013104","journal-title":"Lancet Oncol"},{"key":"1131_CR22","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini\u00a0BI, Plimack\u00a0ER, Stus\u00a0V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N\u00a0Engl J Med 380:1116\u20131127","journal-title":"N Engl J Med"},{"key":"1131_CR23","volume-title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for metastatic renal cell carcinoma: outcomes by IMDC risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study","author":"D Souli\u00e8res","year":"2019","unstructured":"Souli\u00e8res\u00a0D, Plimack\u00a0ER, Rini\u00a0BI et al (2019) Pembrolizumab plus axitinib versus sunitinib as first-line therapy for metastatic renal cell carcinoma: outcomes by IMDC risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. International Kidney Cancer Symposium (IKCS), Miami, Florida, November 15\u201316, 2019"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01131-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-020-01131-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01131-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T00:42:43Z","timestamp":1611967363000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-020-01131-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1131"],"URL":"https:\/\/doi.org\/10.1007\/s00120-020-01131-x","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,31]]},"assertion":[{"value":"31 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.-O.\u00a0Grimm ist als Berater f\u00fcr folgende Firmen t\u00e4tig gewesen: Amgen, Astellas, Astra Zeneca, Bayer Health Care, Bristol Myers Squibb, ClinSol, Intuitive Surgical, Ipsen, Janssen Cilag, Medac, MSD, Merck Serono, Novartis, ONO Pharma, Pfizer, Sanofi. Er hat Referate f\u00fcr folgende Firmen gehalten: Apogepha, Astellas pharma, Astra Zeneca, Bayer Health Care, Bristol Myers Squibb, Hexal, Ipsen, Janssen Cilag, MSD, Merck Serono, Novartis, ONO Pharma, Pfizer, Pierre Fabre; Forschungsunterst\u00fctzung wurde von Novartis und Bristol-Myers Squibb gew\u00e4hrt. S.\u00a0Foller ist als Berater f\u00fcr folgende Firmen t\u00e4tig gewesen: Roche, MSD, Ipsen. Sie hat Referate f\u00fcr folgende Firmen gehalten: Roche, MSD, Bristol-Myers Squibb, Novartis, Pfizer. Sie hat von der Firma Ipsen ein Honorar f\u00fcr Autorent\u00e4tigkeiten erhalten. V.\u00a0Gr\u00fcnwald gibt an, als Berater f\u00fcr Pfizer, Novartis, Bristol Myer Squibb, Ipsen, Eisai, EUSAPharm, MSD, Merck Serono, Lilly und Roche t\u00e4tig gewesen zu sein. Er hat Honorare von AstraZeneca, Pfizer, Novartis, Bristol Myer Squibb, MSD, Ipsen, Eisai, Lilly und Roche erhalten. V.\u00a0Gr\u00fcnwald besitzt Aktien von AstraZeneca, BMS und MSD. Forschungsunterst\u00fctzung erh\u00e4lt er von Bristol Myer Squibb, MSD, AstraZeneca, Pfizer und Novartis. K.\u00a0Leucht gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}